HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

IMPORTANCE: Glioblastoma is an incurable tumor, and the therapeutic options for patients are limited. OBJECTIVE: To determine whether the systemic administration of HER2-specific chimeric antigen receptor (CAR)–modified virus-specific T cells (VSTs) is safe and whether these cells have antiglioblast...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JAMA Oncol
Κύριοι συγγραφείς: Ahmed, Nabil, Brawley, Vita, Hegde, Meenakshi, Bielamowicz, Kevin, Kalra, Mamta, Landi, Daniel, Robertson, Catherine, Gray, Tara L., Diouf, Oumar, Wakefield, Amanda, Ghazi, Alexia, Gerken, Claudia, Yi, Zhong zhen, Ashoori, Aidin, Wu, Meng-Fen, Liu, Hao, Rooney, Cliona, Dotti, Gianpietro, Gee, Adrian, Su, Jack, Kew, Yvonne, Baskin, David, Zhang, Yi Jonathan, New, Pamela, Grilley, Bambi, Stojakovic, Milica, Hicks, John, Powell, Suzanne Z., Brenner, Malcolm K., Heslop, Helen E., Grossman, Robert, Wels, Winfried S., Gottschalk, Stephen
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5747970/
https://ncbi.nlm.nih.gov/pubmed/28426845
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.0184
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια